FAQ: Branded Legacy's FDA Pathway for Intranasal Naloxone Spray
Summary
Branded Legacy, Inc. is advancing its proprietary intranasal naloxone spray through FDA Pre-ANDA preparation, aiming to provide a cost-effective alternative to Narcan for opioid overdose reversal. This innovation could significantly improve global accessibility to life-saving overdose treatment.
What is the main announcement from Branded Legacy, Inc.?
Branded Legacy announced that its subsidiary, BioLegacy Evaluative Group, has begun preparing its FDA Pre-Abbreviated New Drug Application (Pre-ANDA) briefing package for a proprietary intranasal naloxone spray, following a provisional patent filing for its air-driven delivery platform.
Why is this intranasal naloxone development significant?
This development aims to offer a cost-effective, scalable solution to the opioid overdose crisis by replicating Narcan performance while significantly reducing cost and improving global accessibility for overdose reversal treatment.
How does Branded Legacy’s intranasal platform work?
The platform uses an air-driven delivery system designed to deliver naloxone HCl nasal sprays in 2 mg and 4 mg doses, with the goal of achieving bioequivalence with Narcan while being more cost-effective and accessible.
What testing and documentation is included in the Pre-ANDA submission?
The submission includes a Target Product Profile for 2 mg and 4 mg naloxone HCl nasal sprays, Chemistry, Manufacturing and Controls specifications, a 60-subject bioequivalence study against Narcan, and human factors testing to ensure accessibility for non-medical users.
Who is leading this initiative at Branded Legacy?
Kristian Thorlund, Executive Chair of Branded Legacy, is quoted stating that their intranasal platform aims to replicate Narcan performance while reducing costs and improving accessibility.
What manufacturing capabilities does Branded Legacy have?
Branded Legacy operates a state-of-the-art GMP manufacturing facility in Vancouver, which provides advanced production capabilities for developing and delivering cutting-edge products.
How does this compare to existing naloxone products like Narcan?
The company aims to replicate Narcan’s performance while offering significant cost reductions and improved global accessibility through their proprietary air-driven delivery platform.
Where can I find more information about Branded Legacy?
For more information, visit the company’s website at https://BrandedLegacy.com or view the full press release at https://ibn.fm/UBvl4.
What strategic partnerships does Branded Legacy have?
Branded Legacy collaborates with leading institutions including McMaster University and Stanford University to drive transformative research and innovation in addiction treatment and harm reduction.
What is Branded Legacy’s overall business focus?
Branded Legacy is a holding company focused on life sciences and wellness innovation, specifically dedicated to pioneering solutions in addiction treatment and harm reduction through its subsidiary BioLegacy Evaluative Group.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 261164